TELO

Telomir Pharmaceuticals, Inc. Common Stock

0.71

USD

-0.07

-8.97%

Nov 06, 15:59 UTC -5

Closed

After-Market

0.74

+0.03

+4.91%

Telomir Pharmaceuticals, Inc. Common Stock (TELO) Earnings

TELO Earnings Reports

Positive Surprise Ratio

TELO beat 2 of 5 last estimates.

40%

Next Report

Date of Next Report

Mar 15, 2027

Estimate for Q4 26 (Revenue/ EPS)

$1.02M

-$0.06

Implied change from Q3 26 (Revenue/ EPS)

Implied change from Q4 25 (Revenue/ EPS)

-78.57%

Telomir Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On Nov 06, 2026, TELO reported earnings of -- USD per share (EPS) for Q3 26, -- the estimate of -0.08 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 510.00 thousand, with a --% difference.

Looking ahead to Q4 26, -- analysts forecast an EPS of -0.06 USD, with revenue projected to reach 1.02 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Cronos Group Inc. Common Share

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.03

Actual

$0.04

Surprise

+17.65%

Aclaris Therapeutics, Inc.

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.12

Surprise

+28.49%

Protara Therapeutics, Inc. Common Stock

Report Date

Nov 06, 2026 For Q3 26

Estimate

-$0.37

Actual

-$0.35

Surprise

+6.17%

Minerva Neurosciences, Inc

Report Date

Nov 06, 2026 For Q3 26

Estimate

-$0.12

Actual

$1.94

Surprise

+1,629.97%

Organogenesis Holdings Inc. Class A Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.17

Actual

-$0.25

Surprise

-40.06%

ZOETIS INC.

Report Date

Nov 05, 2026 For Q3 26

Estimate

$1.52

Actual

$1.75

Surprise

+14.64%

Dyne Therapeutics, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.92

Actual

-$1.06

Surprise

-15.57%

Amylyx Pharmaceuticals, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.38

Actual

-$0.38

Surprise

+1.04%

Aldeyra Therapeutics, Inc.

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.09

Actual

-$0.06

Surprise

+37.43%

Lipocine Inc.

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.36

Actual

-$0.08

Surprise

+77.91%

FAQ

What were Telomir Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?

For Q3 2026, Telomir Pharmaceuticals, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.

How did the market react to Telomir Pharmaceuticals, Inc. Common Stock's Q3 2026 earnings?

The stock price moved -- --, changed from -- before the earnings release to -- the day after.

When is Telomir Pharmaceuticals, Inc. Common Stock expected to report next?

The next earning report is scheduled for Mar 15, 2027.

What are the forecasts for Telomir Pharmaceuticals, Inc. Common Stock's next earnings report?

Based on -- analysts, Telomir Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.06 and revenue of $1.02M for Q4 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.